The presentations will be broadcasted live even reaching audience outside the meeting and abroad. Links to the presentations will be available on: https://www.biostock.se/
We welcome you to hear our presentation live or register online!
(Attendance and online registration are free of charges.)
2021-01-20ImmuneBiotech closes fully subscribed new share issue with funding from recognized investors and existing shareholders
2020-06-10ImmuneBiotech: Starts clinical trial of GutMagnific® in ME/CFS in collaboration with Stora Sköndal ME clinic
2019-01-24ImmuneBiotech closes new share issue with funding from recognized international investors and business angels
2018-05-29ImmuneBiotech´s scientifically designed probiotic product closer to the market through financial support by Vinnova
ImmuneBiotech AB has been awarded a grant by Innovationskontor Syd to support the development of a probiotic based therapy for one of the most prevalent, wide spread diseases, Irritable Bowel Syndrome (IBS).
2019-11-24 Podcast and interview with Shahram Lavasani on Entrepreneurship and story of ImmuneBiotech
2019-11-07 Shahram Lavasani receives prestigious invitation to attend scientific talk show(Om X antal År), organized by Medicon Village and the daily journal of Sydsvenskan, led by Jesper Rönndahl (Swedish TV-host and comedian), with the focus on Prevention – innovations that contribute to improving health.
ImmuneBiotech is located at Lund´s most attractive Science and Business Park—Medicon Village.
More news on activities in Medicon Village:
- Framtidens Medicon Village
- Shahram Lavasani var en av personerna på scen i showen “Om X Antal År”på Medicon Village.
2019-10-16 Shahram Lavasani, Founder and CEO of ImmuneBiotech, receives expert invitation to ME/CFS union-RME´s closed meeting in Stockholm.
2019-10-08 Shahram Lavasani gives Keynote speech at Synapse-Life Science Connect at Medicinteknik i Skåne, Skane University Hospital
2019-03-21 Shahram Lavasani, CEO at ImmuneBiotech, is invited to speak at:
The future of Swedish and Danish life science – how to benefit patients
2019-01-24 ImmuneBiotech were celebrated at SmiLe incubator graduating from the business incubator program. The company has been a member of the SmiLe Alumni community since Februray 2018, ready to face up to a new chapter in its history.
2018-12-18 We have had a great end of 2018 by winning the Entrepreneur Slam Final in Medicon Village in Lund.
2018-12-13Video recorded interview with Shahram Lavasani-the winner of the Entrepreneur Slam 2018-on YouTube
2018-06-27 Swedish news agency Sydsvenskan (8till5): Lundabaserat inkubatorföretag tar hem kontrakt med Europadominant
2018-06-07 Shahram Lavasani is invited to set up and lead the following worskhop in London: Strategic competitive intelligence and the role of the Microbiome in Immuno-Oncology
2018-02-15 Swedish news agency Sydsvenskan (8till5): Tung techprofil investerar i Lundabaserat inkubatorföretag
2018-02-14 Swedish news agency Rapidus newsletter : ImmuneBiotech får miljontillskott från namnkunniga
INVITATIONS TO UPCOMING CONFERENCES IN 2020
The 4th Microbiome Movement- Drug Development Summit, London, UK.
The 7th Microbiome & Probiotics R&D and Business Collaboration Forum, Rotterdam,Netherlands.
Translational Microbiome Conference, Boston, USA.
The Gut Week Summit, Barcelona, Spain.
The prestigious European Microbiome Congress, London, UK.
Nov 13-14, 2019
Shahram Lavasani, ImmuneBiotech’s founder and CEO, is invited to speak at Advances in Immuno-Oncology Congress, London, UK.
May 20-21, 2019
Shahram Lavasani speaks at World Vaccine Congress, Washington, USA.
April 14-17, 2019
Shahram Lavasani is invited to the World Immunotherapy Congress as a part of Festival of Biologics in US to open the meeting by holding a workshop on Microbiome and delivering a keynote talk on ImmuneBiotech’s success in designing microbial therapies, San Diego, USA.
March 3-5, 2019
Shahram Lavasani is invited to deliver a keynote talk on ImmuneBiotech’s novel selection platform to develop companion probiotic products, at the 4th Annual European Microbiome Congress, London, UK.
November 13-15, 2018
Shahram Lavasani is invited to present ImmuneBiotech at BIO-Europe side event-Microbiome in collaboration with Medicon Valley Alliance, Copenhagen, Denmark
November 8, 2018
Shahram Lavasani is invited as speaker and chairman at 2nd Annual Microbiome: Translating into Diagnostics and Therapeutics Summit, Vienna, Austria.
October 2-3, 2018
Shahram Lavasani is invited to deliver a keynote talk on the role of microbiome on the cancer immunotherapy, at the Immuno-Oncology, London, UK.
September 26-27, 2018
Shahram Lavasani is invited to deliver a keynote talk on The Pharmaceutical & Healthcare Sciences Society (PHSS) Annual Conference 2018 at the University College London (UCL), London, UK.
September 11, 2018
Shahram Lavasani is invited as speaker and chairman at the The Gut-Brain Axis 2018 conference, Paris, France.
September 6-7, 2018
Shahram Lavasani has received an exclusive invitation to attend the Founders Forum London – HealthTech 2018 and speak at the very special Biome Tech session.
June 14, 2018
As an honorary member of the Microbiome Director´s Club Shahram Lavasani is invited to attend the 2nd Annual Microbiome Discovery and Development Congress, Berlin, Germany.
June 7-8, 2018
May 23, 2018
ImmuneBiotech has been chosen for a final Pitch:
Shahram Lavasani has received an exclusive invitation from Helmsley Charitable Trust and the Kenneth Rainin Foundation in New York to attend and contribute to workshop about Diet and Inflammatory Bowel Disease (IBD). New York, USA.
April 19, 2018
Shahram Lavasani is an invited speaker at Microbiome Therapeutics. Amsterdam, The Netherlands.
March 14 – 15, 2018
Shahram Lavasani is an invited speaker at Pharmaceutical Microbiology in London, UK.
January 22–23, 2018
ImmuneBiotech is attending to the Nordic Life Science (NLS) Days in Malmö, Sweden.
September 12-14, 2017
European Microbiome Congress, London, UK
ImmuneBiotech has been selected to PITCH YOUR MICROBES at the Congress
November 30-December 1, 2016
JLINX Symposium, Janssen Pharmaceutica, Beerse, Belgium
October 19, 2016
Nordic Life Science Days in Stockholm
September 14-15, 2016
BioEurope Spring 2016
April 3-6, 2016
Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells.
Nouri M, Bredberg A, Weström B, Lavasani S.
PLoS One. 2014 Sep 3;9(9)
Targeting versus tinkering: explaining why the clinic is frustrated with molecular mapping of disease mechanisms.
Bredberg A, Lavasani S.
Med Hypotheses. 2013 Oct;81(4):553-6
A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells.
Lavasani S, Dzhambazov B, Nouri M, Fåk F, Buske S, Molin G, Thorlacius H, Alenfall J, Jeppsson B, Weström B.
PLoS One. 2010 Feb 2;5(2)
ImmuneBiotech in the News
- The rapid increase of rapid microbial testing – Market to reach $19.5 billion by 2022
- Intestinal Barrier Dysfunction Develops at the Onset of Experimental Autoimmune Encephalomyelitis
- Skador på tarmbarriären vid Multipel Skleros
- Intestinal barrier damage in Multiple Sclerosis
- Leaky gut implicated in Multiple Sclerosis
- Which comes first: the leaky gut or the dysfunctional immune system?
- Dr. Terry Wahls Defeats Multiple Sclerosis Naturally
- Bowel Diseases Related to Multiple Sclerosis
- Probiotic bacteria as new weapon against Multiple Sclerosis
- Our new ideas and hypothesis on how to treat diseases
- Probiotiska bakterier nytt vapen mot Multipel Skleros